Kuros Biosciences entered into a private label agreement with SeaSpine.
Per the agreement, Kuros will supply various bone grafts while SeaSpine will market the products under the brand name OsteoCurrent.
SeaSpine will sell the bone grafts in the U.S. as well as other markets in Europe, South America and the Middle East. The first sales in the U.S. are expected before the end of the first half of 2019.
Terms of the agreement were not disclosed.
Kuros' bone graft technology comprises biphasic calcium phosphate with advanced submicron surface technology that is designed to direct bone formation after implantation.
Joost de Bruijn, CEO of Kuros, said "This is an important agreement, which demonstrates the interest of global orthobiologic companies in Kuros' technologies and should allow greater penetration of our bone grafting technologies into the U.S. and other markets. We look forward to working together with SeaSpine to make OsteoCurrent a success and to improving the bone grafting options for surgeons."